


PCT
410 Rec'd PCT/PTO 07 MAR 2000

FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		017227/0156	
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) UNASSIGNED	
INTERNATIONAL APPLICATION NO. PCT/AU98/00724		INTERNATIONAL FILING DATE 04 September 1998	PRIORITY DATE CLAIMED 08 September 1997
TITLE OF INVENTION TREATMENT OF OBESITY			
APPLICANT(S) FOR DO/EO/US Frank Man-Woon NG and Woei-Jia JIANG			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input checked="" type="checkbox"/> A copy of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11. to 16. below concern other document(s) or information included:			
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information:</p>			



U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.50)
UNASSIGNED
89/508054INTERNATIONAL APPLICATION NO.
PCT/AU98/00724ATTORNEY'S DOCKET NUMBER
017227/0156

17. <input checked="" type="checkbox"/> The following fees are submitted:							CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO \$840.00								
International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00								
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$690.00								
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00								
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00								
ENTER APPROPRIATE BASIC FEE AMOUNT =							\$970.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))								
Claims	Number Filed	Included in Basic Fee	Extra Claims		Rate			
Total Claims	17	-	20	= 0	x	\$18.00	\$0.00	
Independent Claims	5	-	3	= 2	x	\$78.00	\$156.00	
Multiple dependent claim(s) (if applicable)				\$260.00				
TOTAL OF ABOVE CALCULATIONS =							\$1126.00	
Reduction by ½ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).							\$0.00	
SUBTOTAL =							\$1126.00	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).							+	
TOTAL NATIONAL FEE =							\$1126.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property							+	
TOTAL FEES ENCLOSED =							\$1126.00	
							Amount to be: refunded	\$
							charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1126.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$-0- to the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPONDENCE TO:								
Foley & Lardner Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109				SIGNATURE  NAME STEPHEN A. BENT				
REGISTRATION NUMBER 29,768								

428 Rec'd PCT/PTO 07 MAR 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of Frank Man-Woon NG et al.

Serial No. UNASSIGNED

Filed: March 7, 2000

For: **TREATMENT OF OBESITY****PRELIMINARY AMENDMENT**Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application, Applicant respectfully requests that the following amendments be entered into the application:

IN THE CLAIMS:

Please cancel Claim 35 in its entirety, without prejudice or disclaimer.

Claim 17, line 3, delete "any one of claims 1 or 7 to 16" and insert --claim 1--.

Claim 34, line 1, delete "or claim 18".

Claim 36, line 3, delete "any one of claims 1 to 7 or 16" and insert --claim 1--.

Please insert the following new claims:

--37. A pharmaceutical composition for use in the treatment of obesity in an animal, which comprises an effective amount of a peptide according to claim 16, together with one or more pharmaceutically acceptable carriers and/or diluents.

38. A method for the treatment of obesity in an animal, which comprises administering to the animal an effective amount of a peptide according to claim 16.--

REMARKS

Applicants respectfully request that the foregoing amendments to Claims 17 and 34-36, and therefore adding new claims 37 and 38 be entered. These amendments are being made in order to avoid this application incurring a surcharge for the presence of one or more multiple dependent claims. No new matter has been added.

Respectfully submitted,



Stephen A. Bent
Reg. No. 29,768

March 7, 2000
Date

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, DC 20007-5109

- 1 -

TREATMENT OF OBESITY

FIELD OF THE INVENTION

5

This invention relates to the treatment of obesity in animals. In particular, the invention relates to the treatment of obesity in humans, although it is to be understood that the present invention also extends to the treatment of obesity in non-human mammals, for example, for the improvement of meat qualities in farm animals used in food production.

10

BACKGROUND OF THE INVENTION.

15

The critical role of human growth hormone (hGH) in postnatal growth in humans is well recognised. Less obvious is the impact of this hormone on the regulation of lipid and carbohydrate metabolism, due to lack of detailed molecular studies.

20

It is well documented that the predominant form of hGH is a globular protein with a molecular weight of 22,000 daltons (22-KD) and consists of 191 amino acid residues in a single-chain, folded by 2 disulphide bonds with a small loop at the carboxyl terminus between residues 182 and 189. Recent crystallographic studies also show that the hGH molecule contains four anti-parallel α -helices which are arranged in a left-twisted, tightly-packed helical bundle¹. The concept that there are discrete functional domains within the hGH molecule responsible for specific metabolic actions of the hormone is generally accepted. The amino-terminus has been identified as the functional domain responsible for the insulin-like actions of the hGH molecule^{2,3}.

25

RECEIVED AT THE AUSTRALIAN PCT RECEIVING OFFICE
ON 12 NOVEMBER 1998

Recombinant DNA technology opens the way to the large-scale commercial production of human growth hormone, and the recombinant hGH appears to have equivalent biological efficacies and pharmacokinetic properties^{4,5}. Current supply of this multiple-functional hormone no longer restricts the types and numbers of experimental therapies in humans and animals. The use of hGH for treatment of short stature in children and adults is well-established⁶. Therapeutic effects of hGH in female infertility have also been reported^{7,8}. Treatment of human obesity with hGH encounters a variety of problems. Evidence suggests that this multiple-functional hormone often simultaneously exerts *in vivo*, by various bioactive domains within the molecules, some adverse effects^{9,10}.

Regulation of lipid metabolism by GH was first described in 1959 by Raben & Hollenberg¹¹. The regulatory role of the hormone in lipid metabolism was subsequently supported by the body composition studies of GH-deficient and GH-treated humans^{12,13} and pigs^{14,15}. The findings of Gertner suggest that hGH is linked to adipose tissue distribution through a series of interactions known as the "GH-fat cycle"¹⁶. However, the molecular events transpiring to these biochemical and physiological changes remained largely unknown. The metabolic effects of GH on adipose and other tissues *in vivo* are variable and complex, apparently consisting of at least two components, an early insulin-like effect followed by a later more profound anti-insulin effect¹⁷. The results of the latter effect may include both a stimulation of lipolysis and an inhibition of lipogenesis. The anti-lipogenic effect of hGH has been substantiated with the demonstrations of the decrease of the expression of glucose transporter GLUT 4 in adipocytes¹⁸, the inhibition of the activity of acetyl-CoA carboxylase in adipose tissues^{19,20} and the reduction of glucose incorporation into lipid in both isolated cells and tissues^{21,22}.

In view of the multiple-functional effects of intact hGH and the problems encountered in clinical applications of the intact hormone, work leading to the present

09/508054 34

PCT/AU98/00724

Received 10 August 1999

428 Recd PCT/PTO 07 MAR 2000

- 3 -

invention has been directed to investigating whether hGH derivatives could be synthesised that retain the desired bioactivities and lack the unwanted side effects.

The structure-function studies of hGH with synthetic hormonal fragments have
5 revealed that the carboxyl terminus of the hGH molecule appears to be the functional domain of the hormone for the regulation of lipid metabolism^{20,23} and it has been shown that a synthetic peptide having a sequence based in the carboxyl terminal region reduces body weight gain and adipose tissue mass in a laboratory obese animal model.

10

The entire contents of US Patent No. 5869452, issued on Application Serial No. 08/340389, dated 15 November 1994, including the specification, claims and figures, are incorporated herein by reference in their entirety.

15 SUMMARY OF THE INVENTION

The present invention provides a peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone. The peptide may comprise an analogue of the carboxyl-terminal sequence of human growth hormone or the growth
20 hormone of a non-human mammalian species. As described above, the carboxyl-terminal sequence of growth hormone includes a bioactive lipid metabolic domain. In one embodiment of the invention, the peptide comprises an analogue of the carboxyl-terminal sequence of human growth hormone containing amino acid residues 177-191 or a corresponding sequence of a non-human mammalian growth
25 hormone. The analogue may be obtained by insertion, deletion or substitution of amino acids in, or chemical modification of, the native carboxyl-terminal sequence of human growth hormone or the growth hormone of a non-human mammalian species.

In another aspect, the present invention provides a method for treating obesity comprising administering an effective amount of a peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone, as described above. The treatment may be administered to any animal, including humans.

5

The present invention also provides a pharmaceutical composition for use in the treatment of obesity comprising an effective amount of a peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone as described above, together with one or more pharmaceutically acceptable carriers and/or diluents.

10

In yet another aspect, the present invention provides use of a peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone as described above, in the manufacture of a pharmaceutical composition for the treatment of obesity in an animal.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

20

According to one aspect of the present invention, there is provided a method for the treatment of obesity in an animal, which comprises administering to the animal an effective amount of a peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone.

25

Preferably, the animal is a human although the invention also extends to the treatment of non-human mammals. Preferably also, the peptide comprises an analogue of the carboxyl-terminal sequence of human growth hormone containing amino acid residues 177-191 (hereinafter referred to as hGH 177-191). Alternatively, the peptide may comprise an analogue of the carboxyl-terminal sequence of the growth hormone of other non-human mammalian species, such as bovine, porcine,

DOCUMENT FILED
BY FAX

ovine, equine, feline or canine growth hormone, corresponding to the hGH 177-191 peptide.

As used throughout this specification, the term "obesity" is used to include
5 both excess body weight and excess adipose tissue mass in the animal, and correspondingly the references to treatment of obesity include both reduction of body weight gain and reduction of adipose tissue mass of the obese animal.

The expected outcome of any treatment of obesity is the reduction of body
10 weight, body adipose tissue mass in particular. The reduction of body adipose tissue mass is directly regulated by two biochemical processes - lipogenesis (fat-production) and lipolysis (fat-reduction) - and it is generally understood that these biochemical processes are controlled by key metabolic enzymes, specifically the fat-reducing key enzyme (hormone-sensitive lipase) and the fat-producing key enzyme (acetyl CoA
15 carboxylase).

It has been shown by the present inventors that hGH 177-191 is effective in stimulating the fat-reducing key enzyme, hormone-sensitive lipase, and in inhibiting the fat-producing key enzyme, acetyl CoA carboxylase. This is further supported by
20 data showing that in the presence of hGH 177-191, fat utilization is accelerated while fat production is reduced, as measured by metabolic end-products *in vitro* as well as *in vivo*. In addition, the mechanism of these molecular actions has been established as resulting from the activation of the production of the cellular second-messenger, diacylglycerol.

25 It will, of course, be appreciated that the present invention extends to the use of peptides which are analogues of longer amino acid sequences than the particular sequence 177-191 of growth hormone, for example analogues of the sequence 172-191 of human growth hormone or the corresponding sequence of growth hormone
30 of other non-human mammalian species.

The concept of correspondence in amino acid sequences between species is well known in the biological sciences and is determined by aligning comparable sequences (including if necessary theoretical deletions) to match isofunctional or isostereo amino acids thereby maximising homology. The published corresponding 5 sequences of the C-terminus region of the growth hormone of selected mammals are tabulated below²⁶, using standard single letter notation:

	<u>GH Species</u>	<u>Sequence</u>		
	Position	170	180	190
10	human	FRKDMDK	VETFLRIVQCR.	SVEGSCGF
	human variant	FRKDMDK	VETFLRIVQCR.	SVEGSCGF
	human CS	FRKDMDK	VETFLRMVQCR.	SVEGSCGF
	monkey, rhesus	FRKDMDK	IETFLRIVQCR.	SVEGSCGF
	rat	FKKDLHKA	EITYLRVMKCRRFAESSCAF	
	mouse	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
	hamster	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
	whale, fin	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
	whale, sei	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
	fox, dog, cat	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
15	mink	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
	cattle	FRKDLHK	TETYLRVMKCRRFGEASCAF	
	sheep	FRKDLHK	TETYLRVMKCRRFGEASCAF	
	goat	FRKDLHK	TETYLRVMKCRRFGEASCAF	
	pig	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
	alpaca	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
20	horse	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
	elephant	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
	ancestral mammal	FKKDLHKA	EITYLRVMKCRRFVESSCAF	
25				
30				

The present invention extends to the use of peptides which are analogues of the native carboxyl-terminal sequences of human growth hormone or growth 35 hormone of other animal species, and which are derived from natural or synthetic (including recombinant) sources, provided always that the resulting peptide retains the biological activity of the native carboxyl-terminal sequence described herein, namely the ability to reduce body weight gain and adipose tissue mass in an obese

animal. In particular, these analogues may exhibit a cyclic configuration, which may be induced by a disulfide bond.

The analogues of the present invention may be derived by elongation, insertion, deletion or substitution of amino acids in, or chemical modification of, or introduction of a cyclic amide bond between the side chains of amino acids of, the native carboxyl-terminal sequence. Amino acid insertional analogues include amino and/or carboxylic terminal fusions as well as intra-sequence insertions of single or multiple (for example, up to 10, preferably up to 5) amino acids. Insertional amino acid sequence analogues are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product. Deletional analogues are characterised by the removal of one or more (for example, up to 5, preferably up to 3) amino acids from the sequence. Substitutional amino acid analogues are those in which at least one amino acid residue in the sequence, preferably one or two, has been replaced by another of the twenty primary protein amino acids, or by a non-protein amino acid. Chemical modifications of the native carboxyl-terminal sequence include the acetylation of the amino-terminus and/or amidation of the carboxyl-terminus and/or side chain cyclisation of the native carboxyl-terminal sequence.

20

Analogues of the native carboxyl-terminal sequences of human growth hormone or growth hormone of other animal species which in particular retain the same conformation, structure and charge characteristics as the native carboxyl-terminal sequences can be expected to exhibit the same or similar biological activity as the native sequences, in particular in the ability to reduce body weight gain and adipose tissue mass in an obese animal.

Whilst the following detailed description refers specifically to analogues of hGH 177-191, it is to be understood that this invention extends to similar analogues

of corresponding peptides of non-human mammalian growth hormone as described above.

Peptides comprising amino acid residues 177-191 of native human growth
5 hormone (hGH 177-191) include the following sequence (Ref No. 9401):

Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

(SEQ ID NO: 1)

Such a native peptide may be in cyclic disulfide form, and may comprise an
10 organic or inorganic acid addition salt.

Analogues of the hGH 177-191 peptide may be obtained by deletion or insertion of one or more amino acid residues at any position along the native sequence, with the retention of anti-obesity properties as described above.

15 Preferably, the analogue is in a cyclic configuration.

Alternatively, analogues of the hGH 177-191 peptide may be obtained by substitution of one or more amino acid residues at any position along the native sequence.

20

Screening for *in vitro* and *in vivo* activity using alanine substitution scanning and other methods reported herein has revealed positions and relationships between amino acids in hGH 177-191 which are important in the bioactivity as described above. Preferred analogues of the current invention include peptide analogues of
25 hGH 177-191 wherein

- (i) amino acids at positions 182 and 189 of hGH are joined by a bond to promote a cyclic conformation; and/or
- (ii) amino acids at positions 183 and 186 of hGH are joined by a salt bridge or a covalent bond.

30

The bond between amino acids at 182 and 189 of hGH may be a disulfide bond, in which case the amino acids at positions 182 and 189 of hGH may preferably be L- or D- Cys or Pen.

5 When the amino acids at positions 183 and 186 of hGH are joined by a salt bridge, these amino acids may preferably be (X and Y) or (Y and X), respectively, where:

X is a positively charged amino acid such as L- or D- Arg, Lys or Orn and
Y is a negatively charged amino acid such as L- or D- Asp or Glu.

10 When the amino acids at positions 183 and 186 of hGH are joined by a covalent bond, that bond may be an amide bond in which case these amino acids may preferably be (X and Y) or (Y and X), respectively, where:

X is selected from the group consisting of L- or D- Lys and Orn and
15 Y is selected from the group consisting of L- or D- Asp and Glu.

The amino acid at position 178 of hGH is preferably a positively charged amino acid such as L- or D- Arg, Lys or Orn.

20 Analogues may also be obtained by elongation of the native hGH 177-191 peptide sequence at one or both ends of the amino acid residues, for example with one or more hydrophilic amino acids to increase solubility in aqueous solution. Such analogues include the following sequence, preferably in cyclic disulphide form:

X¹m-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-X²n

25 (SEQ ID NO: 2)

wherein X¹ and X² are each selected from the group consisting of L- or D-Arg, His and Lys, and m and n are each 0, 1, 2 or 3 with the provision that at least m or n is 1.

[Throughout this specification, elements which are underlined denote differences from the native hGH 177-191 sequence, and unless otherwise stated, amino acids at positions corresponding to 182 and 189 are joined by a disulfide bond.]

5 One elongation analogue not elongated with a hydrophilic amino acid but nonetheless exhibiting especially enhanced anti-obesity properties is the following (Ref No. 9604):

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe.

(SEQ ID NO: 19)

10 Analogues may also be obtained by chemical modification of the native hGH 177-191 peptide sequence. Such analogues include the sequence:

Y¹-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

(SEQ ID NO: 3)

15 wherein Y¹ is selected from the group consisting of the desamino form (H), acetyl (CH₃CO-) and other acyl groups; or the sequence:

Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-Y²

(SEQ ID NO: 4)

20 where Y² is selected from the group consisting of -CONH₂ and alkyl amide groups.

25 Specific hGH 177-191 analogues obtained by substitution of amino acids, by elongation, by chemical modification, or by introduction of a cyclic amide bond between side chains of amino acids, of the native hGH 177-191 peptide sequence, and which exhibit anti-obesity properties, include the following:

Ref No.	STRUCTURE	SEQ ID NO:
30 9502	Leu Arg Ile Val Gln <u>Pen</u> Arg Ser Val Glu Gly Ser <u>Pen</u> Gly Phe	15

- 11 -

	<u>CH₃CO-</u> Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	8
9410	<u>H -</u> Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	12
5	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe - <u>CONH₂</u>	7
9407	Leu Arg Ile Val Gln Cys <u>Lys</u> Ser Val Glu Gly Ser Cys Gly Phe	10
10	Leu Arg Ile Val Gln Cys <u>Lys</u> Ser Val Glu Gly Ser Cys Gly Phe (amide bond)	11
9604	<u>Tyr</u> Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	19
9605	<u>Lys</u> Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	20
15	<u>Lys Lys</u> Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	33
9607	<u>Ala</u> Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	22
20	Leu <u>Lys</u> Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	21
9608	Leu Arg <u>Ala</u> Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	23
9403	Leu Arg <u>Lys</u> Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	6
25	Leu Arg Ile <u>Ala</u> Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	24
9610	Leu Arg Ile Val <u>Ala</u> Cys Arg Ser Val Glu Gly Ser Cys Gly Phe	25
30	Leu Arg Ile Val Gln Cys Arg <u>Ala</u> Val Glu Gly Ser Cys Gly Phe	27
9613	Leu Arg Ile Val Gln Cys Arg Ser <u>Ala</u> Glu Gly Ser Cys Gly Phe	28
9615	Leu Arg Ile Val Gln Cys Arg Ser Val Glu <u>Ala</u> Ser Cys Gly Phe	30
35	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly <u>Ala</u> Cys Gly Phe	31
9602	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys <u>Ala</u> Phe	17
40	Leu Arg Ile Val Gln Cys Arg Ser Val Glu <u>D-Ala</u> Ser Cys <u>D-Ala</u> Phe	14
9601	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly <u>Ala</u>	16

wherein the amino acid residue abbreviations used are in accordance with the standard peptide nomenclature:

	Gly	=	Glycine;	Ile	=	Isoleucine;
5	Glu	=	Glutamic Acid;	Phe	=	Phenylalanine;
	Cys	=	Cysteine;	Arg	=	Arginine;
	Gln	=	Glutamine;	Leu	=	Leucine;
	Ser	=	Serine;	Val	=	Valine;
	Lys	=	Lysine;	Ala	=	Alanine;
10	Asp	=	Aspartic acid;	His	=	Histidine;
	Orn	=	Ornithine;	Tyr	=	Tyrosine;
	Pen	=	Penicillamine (β,β' -Dimethyl-Cysteine).			

All amino acids, except for glycine, are of the L-absolute configuration, unless indicated as D-absolute configuration. All the above peptides above have a cyclic disulfide bond between Cys(182) and Cys(189) or Pen(182) and Pen(189) as appropriate.

Where appropriate, the analogues described above may comprise an organic or inorganic acid addition salt.

The term "effective amount" as used herein means an amount of the peptide sufficient to attain the desired effect in the treatment of obesity in the animal, but not so large an amount as to cause serious side effects or adverse reactions.

25

In another aspect, the present invention provides the use of a peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone as described above, in the treatment of obesity in an animal or in the manufacture of a pharmaceutical composition for the treatment of obesity in an animal.

In yet another aspect, the present invention provides a pharmaceutical composition for use in the treatment of obesity in an animal, comprising an effective amount of a peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone as described above, together with one or more pharmaceutically acceptable carriers and/or diluents.

The peptide which is the active ingredient of the pharmaceutical composition of this aspect of the invention exhibits advantageous therapeutic activity in the treatment of obesity in an animal when administered in an amount appropriate to the particular case. For example, from about 0.5 µg to about 20 mg per kilogram of body weight per day may be administered. Dosage regimens may be adjusted to provide the optimum prophylactic or therapeutic response. For example, one or more divided doses may be administered daily, weekly, monthly or in other suitable time intervals or the dose may be proportionally reduced as indicated by the exigencies of the clinical situation.

The active ingredient may be administered in any convenient manner such as by the oral, parenteral (including intraperitoneal, intravenous, subcutaneous, intramuscular and intramedullary injection), intranasal, intradermal or suppository routes or by implanting (eg using slow release devices). For ease of administration, oral administration is preferred, however parenteral administration is also quite convenient. Depending on the route of administration, the active ingredient may be required to be coated in a material that protects said ingredient from the action of enzymes, acids and other natural conditions which may inactivate the said ingredient. For example, low lipophilicity of the ingredient may allow it to be destroyed in the gastrointestinal tract by enzymes capable of cleaving peptide bonds and in the stomach by acid hydrolysis. In order to administer the composition by other than parenteral administration, the active ingredient may be coated by, or administered with, a material to prevent its inactivation.

The active ingredient may also be administered in dispersions prepared in glycerol, liquid polyethylene glycols, and/or mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations will usually contain a preservative to prevent the growth of microorganisms.

5

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thiomorosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by, for example, the use in the compositions of agents delaying absorption.

DRAFT PCT/EP 2000/000000

25

20

15

10

5

30

Sterile injectable solutions are prepared by incorporating the active ingredient in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilisation. Generally, dispersions are prepared by incorporating the sterilised active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation

are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

5 When the active ingredient is suitably protected as described above, the composition may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral administration, the active ingredient may be
10 incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.01% by weight and more preferably at least 0.1-1% by weight of active ingredient. The percentage of the compositions and preparations may, of course, be varied and may conveniently be
15 between about 5 to about 80% of the weight of the unit. The amount of active ingredient in the pharmaceutical compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention may, for example, be prepared so that an oral dosage unit form contains between about 0.5 µg and 200 mg and more preferably 10µg and 20 mg of active ingredient.
20

25 The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills,
30 or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain

DO NOT DESTROY - A U.S. GOVERNMENT COPY

the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active 5 ingredient may be incorporated into sustained-release preparations and formulations.

As used herein, pharmaceutically acceptable carriers and diluents include any and all solvents, dispersion media, aqueous solutions, coatings, antibacterial 10 and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art, and it is described, by way of example, in *Remington's Pharmaceutical Sciences*, 18th Edition, Mack Publishing Company, Pennsylvania, USA. Except insofar as any conventional media or agent is incompatible with the active 15 ingredient, use thereof in the pharmaceutical compositions of the present invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

It is especially advantageous to formulate compositions in dosage unit form 20 for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the human subjects to be treated; each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier and/or diluent. The specifications for the novel 25 dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active ingredient and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active ingredient for the treatment of obesity.

Throughout this specification and claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

5

Further details of the present invention will be apparent from the following Example and the accompanying drawings which are included by way of illustration, not by way of limitation, of this invention.

10 **BRIEF DESCRIPTION OF THE DRAWINGS.**

In the drawings:

15 **Figures 1A & 1B** show the effect of hGH 177-191 peptide on cumulative body weight gains in male (1A) and female (1B) C57BL/6J (ob/ob) mice during the 18-day treatment period. Animals were given a daily intraperitoneal injection of 0.1 ml of either saline or hGH 177-191 (200 μ g/kg body weight). Each points represents the mean \pm SEM of 6 animals.

20 **Figures 2A & 2B** show the average daily food consumption (g/mouse/day) of C57BL/6J (ob/ob) mice during an 18-day treatment period with hGH 177-191. The treatment for the four groups of animals was as described in figures 1A & 1B. Each point represents the mean \pm SEM of 6 animals. No significance between the groups was observed at all times.

25

30 **Figures 3A & 3B** demonstrate the effect of hGH 177-191 peptide on body weight gain of 14-15 week old male Zucker fatty (fa/fa) rats during the 20 or 27-days treatment period. Animals were given a daily intraperitoneal injection of either saline or the peptide (500 μ g/kg body weight) (3A) or implanted intradermally with a slow-release tablet (500 μ g/day/kg body weight) in the lower quadrant of the

09508057-042000

abdomen of the animals. The control group was implanted with a placebo tablet in the same manner. Each point represents the mean \pm SEM of 6 animals.

5 **Figures 4A & 4B** demonstrate the average daily food consumption (g/rat/day) of Zucker fatty rats during the treatment period with hGH 177-191 peptide. The treatment for the four groups of animals was as described in Figures 3A & 3B. Each point represents the mean \pm SEM of 6 animals. No significance between the test groups and the appropriate controls was observed at all times

10 **Figures 5A & 5B** depict the ex vivo effect on lipogenesis in adipose tissues of the C57BL/6J (ob/ob) male mice (5A) and female mice (5B) after 18-day treatment with hGH 177-191. Data indicate the rate of [C^{14}]-lipid synthesis and are expressed as [C^{14}]-glucose incorporated into lipid (pmol/mg tissue/min). Values are mean \pm SEM of 12 determinations from 6 animals of each group. The differences 15 between the hGH 177-191 treated and saline control groups were statistically significant.

20 **Figure 6A & 6B** depict the ex vivo effect on lipolysis in adipose tissue of the C57BL/6J (ob/ob) male mice (6A) and female mice (6B) after 18-days treatment with hGH 177-191. Data indicate the rate of glycerol release from adipose tissues (pmol/mg tissue/min). Values are mean \pm SEM of 12 determinations from 6 animals of each group. The differences between the hGH 177-191 treated and saline control groups were statistically significant.

25 **Figure 7** illustrates the *in vitro* effect of hGH 177-191 on fatty acid oxidation in isolated adipose tissues of C57BL/6J (ob/ob) mice with the determination of the rate of [C^{14}] O_2 production from [C^{14}]-palmitic acid. The rate of [C^{14}]-palmitic acid oxidation was expressed as μ mol/g tissue/hr.

Figure 8 illustrates the *in vitro* effect of hGH 177-191 on the release of diacylglycerol from isolated adipocytes of normal rats over an incubation period of 40 min. Diacylglycerol was quantitated using radioenzymic assay and the results were expressed as % increase over the basal levels.

5

Figure 9 shows the *in vitro* effect of hGH 177-191 on hormone-sensitive lipase activity in isolated adipocytes of male Zucker fatty (fa/fa) rats was determined by the amount of hydrolyzed [C^{14}]-oleic acid from [C^{14}]-triolein. The enzyme was expressed as U/mg protein, where the release of 1 nmole of oleic acid per hour was considered as 1 Unit of enzyme activity.

10

Figures 10A & 10B shows the *in vitro* effect of hGH 177-191 on acetyl-CoA carboxylase in the isolated adipocytes (10A) and hepatocytes (10B) of normal rats was determined by [C^{14}]-bicarbonate fixation reaction and expressed as mU/g cell dry weight, where 1 Unit of acetyl-CoA carboxylase was defined as the carboxylation of 1 μ mole acetyl-CoA per minute.

15

Figure 11A demonstrates the effect of analogue Ref. No. 9403 (SEQ ID NO: 6) on body weight gain of 26-week-old C57BL/6J (ob/ob) mice during the 18 days treatment period. Animals were given a daily intraperitoneal injection of either saline (as control) or peptide analogue (500 μ g/kg body weight). Each point represents the mean \pm SEM of 6 animals.

20

Figure 11B shows the average daily food consumption (g/mouse/day) of 26-week-old C57BL/6J (ob/ob) mice during the treatment period with analogue Ref No. 9403 (SEQ ID NO: 6). The treatment for the two groups of animals was as described in Figure 11A. Each point represents the mean \pm SEM of 6 animals. No significance between the test group and the control was observed at all times.

25

30

- 20 -

Figure 12 shows the effect on body weight gain of chronic treatment of 16-week old C57BL/6J(ob/ob) mice with analogues Ref Nos. 9604 (SEQ ID NO: 19) and 9605 (SEQ ID NO: 20).

5 **Figure 13** shows the effect of long-term oral administration of analogue Ref No. 9604 to ob/ob mice.

EXAMPLE

10

MATERIALS AND METHODS

Animals and treatments.

Obese C57BL/6J (ob/ob) mice and fatty Zucker (fa/fa) rats were used to demonstrate the biological effects of the synthetic hGH 177-191 and analogues.

15

The animals of the same age and same sex were randomly divided into two groups, housed 6 per cage and maintained on a normal 12-hr light/dark cycle at a constant room temperature of 25°C in the animal house of the Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia. Animals were fed *ad libitum* on pre-determined quantity of animal pellets (Clark King, Melbourne, Australia) and allowed free access to water at all times. The animals were given a daily intraperitoneal (i.p) injection of 0.1 ml of either the synthetic peptide (200-500 μ g/kg body weight) or equivalent volume of physiological saline (0.9% sodium chloride) for appropriate number of days. The i.p. injection was administered with a 30G x ½" (0.31 x 13 mm) needle on a 1-ml disposable tuberculin syringes, and the site of injection was the lower left quadrant of the abdomen of the animals. To study the effects of controlled-delivery of hGH 177-191 and analogues, slow-release peptide-pellets in a diameter of 3 mm were implanted intradermally in the abdominal region of Zucker rats under anaesthesia. The body weight and food intake were monitored for the periods of time as indicated.

20

25

30

DRAFT DRAFT DRAFT DRAFT DRAFT

Peptide Synthesis

The peptides of the present invention were prepared by using standard 9-fluorenylmethyloxycarbonyl(Fmoc) solid-phase techniques. The solid-phase synthesis, for example, could be commenced from the C-terminal end of the peptide
5 using an α -amino protected amino acid. A suitable starting materials could be prepared, for instance, by attaching the required α -amino acid to a Wang resin (4-alkoxybenzyl alcohol resin), or Rink amide resin (2,4-dimethoxy-4'-[carboxymethoxy]-benzhydrylamine linked to amino methyl resin) or PAM resin (4-hydroxymethylphenyl-acetic acid resin). Resins were commercially available from
10 Auspep Pty. Ltd., Parkville, Victoria, Australia.

In the solid-phase preparation of the compounds of this invention, a protected amino acid was coupled to a resin with the aid of a coupling agent. After the initial coupling, the α -amino protecting group was removed by piperidine in
15 organic solvents at room temperature. Following the removal of the α -amino protecting group, the remaining protected amino acids were coupled stepwise in the desired order. A 4-fold excess of each protected amino acid was generally used in the reaction with an appropriate carboxyl group activator such as diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole (HOBt), in methylene
20 chloride (DCM)-N,N-dimethylformamide (DMF) mixtures.

After the desired amino acid sequence was completed, the peptide was then cleaved from the resin support by treatment with a reagent such as trifluoroacetic acid (TFA) or trifluormethanesulfonic acid (TFMSA) which cleaved the peptide from
25 the resin, as well as all side-chain protecting groups, except for Cys(Acm). When a Wang resin was used, TFA treatment resulted in the formation of the free peptide acids. When the Rink amide resin was used, TFA treatment resulted in the formation of the free peptide amides. When a PAM resin was used, TFMSA treatment resulted in the formation of the free peptide acids. The target peptides
30 might exist in cyclic disulfide form which requires post-synthesis modification.

The following examples are provided for the purpose of further illustration only and not intended to be limitations on the disclosed invention.

A. Synthesis of pentadecapeptide comprising amino acid residues 177-191 of native human growth hormone, designated as hGH (177-191) (Ref No. 5 9401):

Leu¹-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe¹⁵ (cyclic disulfide)

The following procedure was employed in preparing the pentadecapeptide:

10 **Step 1.** Wang resin (0.625 g, 0.5 mmol) was placed in a 10 ml-reaction vessel. DCM (4 ml) was added to the reaction vessel. The Wang resin was washed with vigorous stirring for 2 minutes. The DCM solution was then drained from the reaction vessel. This washing was repeated twice.

15 **Step 2.** Fmoc-L-phenylalanine (Fmoc-Phe, 0.388 g, 1.0 mmol) in 2.4 ml NMP-DCM (1:5, v/v) and DIC (0.135 g, 1.0 mmol) in 1.0 ml NMP were mixed in a reaction vessel for 10 minutes. To the mixture, 4-dimethylaminopyridine (DMAP, 0.074g, 0.06 mmol) in 0.6 ml DMF was added. The reaction in the solution was allowed to continue for 68 minutes at room temperature. The solution was then drained, the resin was washed thoroughly with NMP (4 ml x 3) and DCM (4 ml x 3).

20 The Fmoc-Phe-Wang Resin complex was dried *in vacuo* overnight to yield 0.781 g of material. The coupling level of amino acid to resin was determined to be 0.80 mmol/g resin by using spectrophotometric measurement of the Fmoc-piperidine adduct.

25 **Step 3.** Fmoc-Phe-Wang Resin (0.263 g, 0.20 mmol) was placed in the 10 ml-reaction vessel. DMF (8 ml) was added to wash and swell the resin by stirring for 2 minutes. The solution was then drained from the reaction vessel.

30 **Step 4.** A 25% piperidine/DMF solution (4 ml) was added to the reaction vessel. The resulting mixture was stirred for 2 minutes. The solution was drained from the reaction vessel. This deprotection procedure was repeated once

but with prolonged stirring time (18 min). The solution was drained from the reaction vessel.

Step 5. DMF (8 ml) was added to the reaction vessel. The resulting solution was stirred for 2 minutes. The solution was drained from the resin in the 5 reaction vessel. This washing procedure was repeated twice. DMF (2 ml) was added to the reaction vessel to keep the resin swollen.

Step 6. Fmoc-glycine (Fmoc-Gly, 0.238 g, 0.8 mmol), HOBr (108 mg; 0.8 mmol) and DIC (128 µl; 0.8 mmol) were added to a 10 ml-test tube containing 10 2 ml DMF. The mixture was stirred for 10 minutes to start the activation of amino acid. The solution was then added to the resin which originally was placed in the reaction vessel. The resulting mixture was stirred for 1.5 hours or until a negative ninhydrin test was obtained. The solution was then drained from the reaction vessel.

Step 7. DMF (8 ml) was added to the reaction vessel. The resulting 15 solution was vigorously stirred for 2 minutes. The solution was then drained from the reaction vessel. The washing procedure was repeated twice.

Steps 4 through 7 were then repeated employing the following order of amino acid:

- 20 Fmoc-Cys(Acm)
- Fmoc-Ser(t-Bu)
- Fmoc-Gly
- Fmoc-Glu(O-tBu)
- Fmoc-Val
- 25 Fmoc-Ser(t-Bu)
- Fmoc-Arg(Pmc)
- Fmoc-Cys(Acm)
- Fmoc-Gln
- Fmoc-Val
- 30 Fmoc-Ile

Fmoc-Arg(Pmc)

Fmoc-Leu

After completion of the synthesis of the desired peptide-resin, the reaction
5 vessel containing the peptide-resin was then placed in a desiccator and dried
overnight under vacuum. The yield of peptide-resin was 0.635 g. The dried peptide-
resin was removed from the reaction vessel and placed in a 50 ml round-bottom
flask containing a magnetic stirring bar. The cleavage of the peptide from the resin
with TFA was carried out with the following procedure: A scavenger solution,
10 containing 0.75 g phenol, 0.5 ml H₂O, 0.5 ml thioanisole, and 0.25 ml ethanedithio,
was added to the round-bottom flask. The resulting mixture was stirred for 5
minutes. 10 ml TFA was added drop by drop into the flask while kept stirring
vigorously. The resulting mixture was stirred for 2.5 hours at room temperature.

15 The mixture was filtered through a medium-porosity filter, fritted glass funnel.
The TFA-peptide solution was sucked into another 500 ml round-bottom flask
containing 200 mL cold diethyl ether by applying vacuum. Peptide was allowed to
be precipitated in the ether solution at 4 °C overnight, then collected by filtering the
mixture through a fine-porosity, fritted glass funnel. The peptide pellet on the filter
20 was washed with cold ether (10 ml x 3) to remove the scavenger. The peptide pellet
was then dissolved with 25% aqueous acetic acid and then lyophilized to yield the
crude peptide (about 400 mg dry weight, purity ~80%).

The crude peptide was purified by reversed-phase high performance liquid
25 chromatography (RP-HPLC). Purification was carried out on a preparative 21.2 x
250 mm Supelcosil PLC-18 (octadecyl, C₁₈) column(120 Angstrom pore size, 12 µm
particle size, 190 m²/g surface area; Supelco, Bellefonte, PA, U.S.A.) at 5.0 ml/min
flow rate at room temperature. A linear gradient program was utilized , where
solvent A was water with 0.1% TFA, and solvent B was acetonitrile-water (50/50:
30 v/v, containing 0.1% TFA). The gradient was developed from 20 to 100% over 80

min. Separation profiles were recorded and analysed using a Perkin-Elmer LC-100 integrator. The desired peptide component was eluted and collected with the Pharmacia Model FRAC-100 automatic fraction collector (Uppsala, Sweden). The fractions of identical component were combined and lyophilized. The purified 5 peptide (275 mg dry weight, purity >98%), Cys(Acm)^{6,13}-pentadecapeptide, was kept frozen at -20°C.

For cyclisation of the disulfide bridge of the peptides, iodine oxidation in 80% aqueous acetic acid was used to remove the cysteine-protecting groups, Acm, and 10 furnished the intramolecular disulfide bridge simultaneously. Cys(Acm)^{6,13}-pentadecapeptide (275 mg , 0.155 mmole) was dissolved in 50 ml 80% aqueous acetic acid. This solution was slowly added to a 250 ml round-bottom flask containing iodine (378 mg, 1.4 mmole) in 100 ml 80% aqueous acetic acid by stirring vigorously. Reaction was allowed to continue for 2 hours at room 15 temperature and terminated by adding the ascorbic acid (Vitamin C) to the resulting solution. Liquid volume was then reduced by rotary evaporation and peptide recovered by lyophilization. The cyclised peptide was then purified by RP-HPLC as described in the purification of linear peptide. After lyophilization, 165 mg cyclic pentadecapeptide with 96% purity was yielded. The total yield of synthesis was 20 about 46%.

B. Synthesis of pentadecapeptide (Ref No. 9404):

Leu¹-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe¹⁵-CONH₂
25 (cyclic disulfide)

The procedure set forth in EXAMPLE A was employed. The modification consisted of omitting Wang resin and replacing it with the Rink amide resin.

30 C. Synthesis of the pentadecapeptide (Ref No. 9410):

H-Leu¹-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe¹⁵
(cyclic disulfide)

The procedure set forth in EXAMPLE A was employed. The modification
5 consisted of the replacement of Fmoc-Leu and with 4-methyl-pentacarboxylic acid,
resulting in the synthesis of the desamino pentadecapeptide.

D. Synthesis of the pentadecapeptide (Ref No. 9405):

10 CH₃CO-Leu¹-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe¹⁵
(cyclic disulfide)

The procedure set forth in EXAMPLE A was employed. After completion of
the synthesis of the desired deblocked peptide-resin, 5 ml solution of 20% acetic
15 anhydride in DMF was added. After 5 minutes, 71 µl (0.4 mmols) of
diisopropylethylamine (DIEA) was added to neutralize the protons that were
generated. Acetylation of the peptide was performed at room temperature for 30
minutes. The peptide-resin was washed twice with DMF and twice with DCM and
the N-acetyl peptide resin was ready for TFA cleavage as shown in EXAMPLE A.

20

E. Synthesis of the dicyclo-pentadecapeptide (Ref No. 9408):

| |
Leu¹-Arg-Ile-Val-Gln-Cys-Lys-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe¹⁵
(cyclic disulfide)

25

The following procedure was employed in preparing the pentadecapeptide:

Step 1. Boc-L-phenylalanine-PAM resin (0.400 g, 0.2 mmol; Auspep,
Melbourne, Australia; Cat#5290F, Batch#494123) was placed in a 10ml reaction
vessel. The resin was washed with DCM (4 ml) by vigorous stirring for 2 minutes.

30 The DCM solution was then drained from the reaction vessel. This washing was
repeated once.

DOCUMENT FILE NUMBER

Step 2. 50% TFA/DCM solution (4 ml) was added to the reaction vessel. The resulting mixture was stirred for 2 minutes. The solution was then drained from the reaction vessel. This deprotection procedure was repeated once with a stirring time of 18 minutes. The solution was drained from the reaction vessel. DCM (4 ml) was added to the reaction vessel and the content was allowed to stand for 2 minutes. The solution was again drained from the resin. This washing procedure was repeated twice. 10% DIEA/DMF (4ml) was added to the reaction vessel. The resulting mixture was allowed to stand for 1 minute and the solution removed as before. This deprotection procedure was repeated once. DMF (4ml) was added to the resin complex in the reaction vessel. The resulting solution was allowed to stand for 2 minutes, followed by the removal of the solution from the vessel. This washing procedure was repeated four times. Finally, DMF (2 ml) was added to the reaction vessel to keep the resin swollen.

Step 3. Fmoc-glycine (Fmoc-Gly, 0.238 g, 0.8 mmol), HOBr (108 mg; 0.8 mmol) and DIC (128 μ l; 0.8 mmol) were added to a 10 ml-test tube containing 2 ml DMF. The mixture was stirred for 10 minutes to activate the amino acid. The solution was then added to the resin in the reaction vessel. The resulting mixture was stirred for 1.5 hours or until a negative ninhydrin test was obtained. The solution was then drained from the reaction vessel.

Step 4. DMF (8 ml) was added to the reaction vessel. The resulting solution was vigorously stirred for 2 minutes, followed by the removal of the supernatant. The washing procedure was repeated twice.

Step 5. 25% piperidine/DMF solution (4 ml) was added to the reaction vessel. The resulting mixture was stirred for 2 minutes. The solution was drained from the reaction vessel. This deprotection procedure was repeated once with stirring for 18 minutes. The solution was drained from the reaction vessel.

Step 6. DMF (8 ml) was added to the reaction vessel. The resulting solution was stirred for 2 minutes. The solution was drained from the reaction vessel resin. This washing procedure was repeated twice. 2 ml DMF was added to the reaction vessel to keep the resin swollen.

Steps 3 through 6 were then repeated with the following order of amino acids:

Fmoc-Cys(Acm)

Fmoc-Ser(Bzl)

5 Fmoc-Gly

Fmoc-Glu(O-tBu)

Fmoc-Val

Fmoc-Ser(Bzl)

10 **Step 7.** Steps 3 and 4 were repeated to couple Fmoc-Lys(Boc) to Ser in the position 184. After completion of coupling, the reaction vessel containing the peptide-resin was then placed in a desiccator and dried overnight under vacuum. the peptide-resin was then transferred to a 10ml-reaction vessel. DCM (4 ml) was added to the reaction vessel. The resin was washed with vigorous stirring for 2 minutes. The DCM solution was then drained from the reaction vessel. This washing was repeated once.

15 **Step 8.** Step 2 was used to remove the Boc group and the t-Bu group from the side chain of lysine and glutamic acid, respectively.

20 **Step 9** 1 ml of 1.5% DIEA/DMF was added to the reaction vessel. Benzotriazo-1-yl-oxy-tris-(dimethylamino)phosphonium hexafluorophosphate (BOP) (400 mg; 0.90 mmol), HOBt (122 mg, 0.90 mmol), and DIEA (400 µl, 2.25 mmol) were dissolved in 3.4 ml of 1.5% DIEA/DMF and then added to the reaction vessel. The resulting mixture was stirred for 3 hours or until a negative ninhydrin test was obtained before the removal of the supernatant from the reaction vessel. DMF (8 ml) was then added to the reaction vessel. The resulting solution was vigorously stirred for 2 minutes. The solution was then drained from the reaction vessel. The washing procedure was repeated twice.

25 **Step 10.** Steps 5 through 6 were then repeated to remove the Fmoc group from the α -amino group of the lysine residue in the peptide-resin.

Steps 3 through 6 were then repeated with the following order of amino acids:

Fmoc-Cys(Acm)

Fmoc-Gln

Fmoc-Val

5 Fmoc-Ile

Fmoc-Arg(Pmc)

Fmoc-Leu

5 Fmoc-Ile
Fmoc-Arg(Pmc)
Fmoc-Leu

After completion of the synthesis of the desired peptide resin, Step 4 was then

10 repeated to remove the Fmoc group from Leu and get the deblocked peptide resin.

The reaction vessel containing the peptide resin was then placed in a desiccator and dried overnight under vacuum. 604 mg peptide-resin was yielded. The dried peptide resin was removed from the reaction vessel and placed in a 25 ml round-bottom flask containing a magnetic stirring bar. Trifluoromethanesulfonic acid

(TFMSA)/TFA cleavage protocol was used to cleave peptide from the PAM resin: A scavenger solution, containing 500 µl thioanisole, and 250 µl ethanedithio, was added to the flask. The resulting mixture was stirred for 10 minutes at room temperature. 5 ml of TFA was added drop by drop into the flask while kept stirring vigorously. The resulting mixture was stirred at room temperature for 15 minutes

20 Place the flask in an ice-bath and then 500 ml of TFMSA was slowly added while kept stirring vigorously. The resulting mixture was stirred in the ice-bath for 10 minutes and at room temperature another 15 minutes. Cold diethyl ether (50 ml) was added to the flask to stop the reaction and precipitate the cleaved peptide. The peptide was collected by filtering the mixture through a fine-porosity, fritted glass

25 funnel and washed with cold ether (10 mL x 3) to remove the scavenger. The peptide pellet was dissolved with 30 ml of 50 % acetonitrile/H₂O followed by the addition of 5 ml of cold 10% NH₄HCO₃ to neutralize the solution. The crude peptide (519 mg, purity ~69%) was obtained after lyophilization.

The preparation of peptide with cyclic disulfide form and the purification of pure final product are shown in EXAMPLE A.

F. Synthesis of the hexadecapeptide (Ref No. 9604)

5

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (*cyclic disulfide*)

The procedure set forth in Example A was employed, modified by the addition of a further repetition of the steps 4 to 7 using Fmoc-Tyr(t-Bu).

10

Cumulative weight gain and food consumption.

Cumulative weight gain and food consumption were determined at 3-day intervals by the measurements of body weight and uneaten food remaining in the cages. The animals were placed in a covered chamber to minimise movement during the weighing procedure. The food consumption data were obtained by subtracting the amount of uneaten food remaining in the cages from the original provision.

Assays for plasma triglyceride and total cholesterol.

The animals were anaesthetised with sodium pentobarbitone (80 mg/kg body weight) 12 hr after the last dose of hGH 177-191. Blood samples were collected from the tail vein of anaesthetised animals 45 mins after the administration of anaesthetic. After being centrifuged at 2000 x g for 5 minutes, plasma was removed from the samples and used for metabolite assays. Triglyceride and total cholesterol in plasma were measured by enzyme-spectrophotometric methods. The reagents are based on either a modified glycerol phosphate oxidase (GPO)-Trinder's type colour reaction²⁴ or a cholesterol oxidase-4-aminoantipyrine method²⁵. All assays were performed with the CentrifilChem System 400 (Union Carbide) containing an automated pipetter, a centrifugal analyser and a recording

spectrophotometer. Seronorm Lipid (Nycomed Pharma Co., Oslo, Norway) was used as the calibrator.

Determination of adipose tissue weight.

The procedure for the isolation and measurement of intact epididymal fat pads was established in previous studies of epididymal growth of GH-deficient (lit/lit) mice. In the present study, white adipose tissues, either whole epididymal or parametrical fat pads, were excised with the identical techniques as previously described²² from the mice immediately after sacrifice. The tissues were washed in cold physiological saline, blotted and weighed. For ex vivo lipogenic assays, the portions of adipose tissues without blood vessels were used.

Hormone-sensitive lipase (HSL) Assay

Hormone-sensitive lipase (HSL) activity of isolated adipocytes was used as a model to evaluate the lipolytic effect of hGH 177-191 peptide and analogues. In this assay [C^{14}]-triolein was used as a substrate by HSL. The amount of hydrolyzed [C^{14}]-oleic acid was determined and used as an index of HSL activity.

The adipocytes were prepared from the epididymal fat pads of male Zucker fatty (fa/fa) rats by collagenase digestion. Fat pads (5 g) were finely-cut into small (2 -3 mm) pieces and placed in a siliconised glass vial containing 10 ml digestion medium. The digestion medium contained microbial collagenase (Type II) at a concentration of 1 mg/ml in Krebs-Ringer phosphate buffer (pH 7.4) at half Ca^{2+} strength, at 2% (w/v) of bovine serum albumin (BSA Fraction V). After digestion at 37°C for 1 hr under an atmosphere of 95% O_2 /5% CO_2 , adipocytes were liberated from any remaining pieces of adipose tissue by gently sucking the suspension up and down with a 5.0 ml pipette with the tip opening of 3 - 4 mm. The adipocytes released from tissue were then filtered through nylon chiffon into a siliconised glass tube and washed twice with 6 ml of collagen free albumin buffer. The isolated adipocytes were resuspended with 10 ml collagen-free buffer and the concentration

of adipocytes was estimated by counting an aliquot of a pre-determined volume of cells on a microscope slide. It normally gave approximate 10^9 cells/ml of adipocytes in Krebs-Ringer phosphate buffer (pH 7.4).

5 The HSL activity was measured at 37 °C for 1 hour in a final volume of 200 µl, containing 10 µmoles phosphate buffer (pH 7.0), 15 µmoles of emulsified [C^{14}]-triolein, and 10^8 cells. The substrate, [C^{14}]-triolein, was pre-emulsified with unlabelled triolein to provide the final emulsion contains 15 µmoles of triolein and 375,000 cpm in 0.1 ml.. Different concentrations of hGH 177-191 peptide or
10 analogues were added to evaluate their effects on the HSL activities. The reaction was stopped by adding 1 ml of the fatty acid extraction mixture of chloform-methanol-benzene 2:2:4:1 containing 50 µg oleic acid, followed by adding 67 µl of 0.5N NaOH. To extract and isolate free fatty acid, samples were vortexed for 20 seconds and then centrifuged at 1,000 x g for 5 minutes. A 200 µl portion of the
15 alkaline aqueous upper phase containing fatty acids was transferred to scillation vials. The [C^{14}]-radioactivity was measured by a liquid scillation counter. The remaining cell suspension was assayed for protein content.. The HSL activity was expressed as U/mg protein, where the release of 1 nmole of oleic acid per hour was defined as 1 U of enzyme activity.

20

Acetyl-CoA Carboxylase Assay

25 Acetyl-CoA carboxylase catalyzes the critical step in fatty acid synthesis. The acetyl-CoA carboxylase activities of both isolated adipocytes and hepatocytes in the presence of hGH 177-191 peptide or analogues were measured for the evaluation of the anti-lipogenic effect of the peptides. The acetyl-CoA carboxylase activity was determined by the [C^{14}]-bicarbonate fixation reaction - the rate of incorporation of acetyl-CoA dependent $H[C^{14}]O_3$ into [C^{14}]-malonyl-CoA.

DRAFT - INTERNAL USE ONLY

- 33 -

Adipocytes were prepared with the method described in the HSL assay. Hepatocytes were prepared from the livers of male Wistar rats by collagenase digestion. The liver was finely-cut with scissors and transferred to a 250 ml Erlenmeyer flask containing 30 ml of digestion medium. The digestion medium 5 contained microbial collagenase (Type IV) at a concentration of 30 mg/ml in calcium-free Krebs-Ringer phosphate buffer (pH 7.4) and glucose (5 mM). After digestion for 15 minutes at 37°C under an atmosphere of 95% O₂/5% CO₂ the hepatocytes liberated from the tissue were then filtered through nylon chiffon into a siliconised glass tube and washed twice with fresh collagen-free digestion 10 medium. The isolated cells were resuspended in 45 ml of medium containing extra EDTA (0.45 mmoles), gelatine (0.7 ml), 2-{[tris(hydroxymethyl)methyl]amino} ethane sulphonic acid (TES) (0.9 mmoles), and gassed with 95% O₂/5% CO₂ prior to use.

The isolated cells were first preincubated at 37°C for 30 minutes in a mixture 15 containing 50 mM Tris-HCl buffer (pH 7.5), 10 mM potassium citrate, 10 mM MgCl₂, 1 mM dithiothreitol (DTT), and BSA (0.8 mg/ml). The reaction was then initiated by the adding an aliquot of the preincubated cells to an assay mixture (final volume, 500 µl) containing 50 mM Tris-HCl buffer (pH 7.5), 10 mM potassium citrate, 10 mM MgCl₂, 1 mM dithiothreitol (DTT), BSA (0.8 mg/ml), 3.75 mM ATP, 0.125 mM acetyl- 20 CoA, and 12.5 mM NaH[C¹⁴]O₃ (0.44 µCi/µmol). After incubation at 37° C for 10 minutes, the reaction was terminated with 0.1 ml of 6M HCl. The reaction mixture was then allowed to stand in a vacuum desiccator for 30 minutes to remove the unreacted NaH[C¹⁴]O₃ and followed by centrifugation at 1500 g for 10 minutes to eliminate the insoluble material. A 0.5 ml aliquot of the supernatant was taken and 25 transferred to scintillation vials. The [C¹⁴] radioactivity was measured with a liquid scintillation counter. The remaining cell suspension was assayed for protein content. Specific activity of the enzyme was expressed as mU/g cell dry weight, where 1 U of acetyl-CoA carboxylase was defined as that amount which catalyzed the carboxylation of 1 µmole acetyl-CoA per minute.

Assay for lipolytic activity

The lipolytic action of hGH 177-191 and analogues on the isolated adipose tissues was demonstrated by the release of glycerol and free fatty acid (FFA) into the medium during incubation at 37°C.

5

Adipose tissues were removed from animals and sliced into segments of approximately 200 mg each. Then the tissues were pre-incubated in 25 ml vials containing 2 ml of Krebs-Ringer bicarbonate (KRB) buffer, 4% defatted BSA and 5.5 mM glucose under an atmosphere of carbogen (95%O₂/ 5%CO₂) at 37°C for 1

10 hour. Tissues were then transferred to another vials with fresh medium and the incubation was initiated by adding hGH 177-191 peptide or analogues into the vials. The mixtures were then incubated at 37°C for 90 minutes. After incubation, the tissues were removed and aliquots (200 µl) of samples withdrawn from the medium were assayed for the contents of glycerol or free fatty acid (FFA) either by the 15 enzyme assay (glycerol kinase) or colorimetric (copper-dye) spectrometry. The NADH or color produced was then monitored by the absorption at 340 nm and 610 nm, respectively.

Assay for Oxidation of Free Fatty Acid

20 The effect of hGH 177-191 or analogues on the free fatty acid (FFA) oxidation in the adipose tissues is evaluated by the measure of converted [C¹⁴]O₂ from C¹⁴-palmitic acid. The [C¹⁴]O₂, a final product of FFA oxidation, was trapped by hyamine hydroxide and measured by liquid scintillation counter. The rate of FFA oxidation was then determined by [C¹⁴] radioactivity.

25

Adipose tissues removed from laboratory animals were sliced into segments of approximately 200 mg each. The tissues in 25 ml vials containing 2 ml of Krebs-Ringer phosphate (KRP) buffer, and 2% defatted bovine serum albumin (BSA) were pre-incubated at 37°C for 30 minutes under an atmosphere of carbogen (95%O₂/ 30 5%CO₂). Then the tissues were transferred to Konte flasks with fresh incubation

medium with 0.15 mM sodium [C^{14}]-palmitate (final [C^{14}]-specific activity, 0.20 μ Ci/ μ mol) and hGH 177-191 peptide or analogues (1 - 1000 nM). A filter paper roll was placed in a well inside of flask and then the flask was seal with rubber septum stopper. The incubation at 37°C was lasted for 1 hour under an atmosphere of carbogen and was then terminated by injecting 250 μ l of 4.5 M H₂SO₄ with a needle through the rubber septum into the medium of a flask and 250 μ l of hyamine hydroxide was injected to the filter paper roll in the centre well. Flasks were incubated for a further 1 hour to complete the absorption of [C^{14}]O₂ by hyamine hydroxide. The filter paper rolls were then removed and transferred to scintillation vials. The [C^{14}] radioactivity was measured with a liquid scintillation counter. The rate of [C^{14}]-palmitic acid oxidation to [C^{14}]O₂ was calculated and expressed as μ mol/g tissue/hr.

Assay for Lipogenic activity

The rate of the incorporation of exogenous [C^{14}]-glucose into total lipid in adipose tissue was measured as the index of anti-lipogenic activity of hGH 177-191.

Adipose tissues were sliced into segments of approximately 200 mg each and then placed in Krebs-Ringer bicarbonate (KRB) buffer (pH 7.4) containing 2% defatted BSA, and glucose (0.1 mg/ml) and gassed with 95% O₂ - 5% CO₂ at 37 °C. After 1 hr preincubation, the tissues were transferred to another 2 ml of fresh media containing [C^{14}]-glucose (final specific activity 0.05 μ Ci/ μ mol), and 0.3 μ M of hGH 177-191 in the presence or absence of insulin (0.1 mU/ml) for a further 90 min incubation (conditions as above). Then the tissues were removed, washed thoroughly with KRB buffer and lipid was extracted with 5 ml of chloroform/methanol (2:1, v/v) The extraction solution was washed with 2 ml of MeOH-H₂O solution containing 0.1% MgCl₂. A 2.5 ml aliquot of the washed extraction solution was taken and transferred to scintillation vials. The [C^{14}] radioactivity was measured with a liquid scintillation counter. The rates of total lipid synthesis were expressed as μ mol [C^{14}]-glucose incorporated into lipid/g tissue/hr.

Assays for diacylglycerol (DAG) release

Diacylglycerol released from isolated adipose tissue or adipocytes was quantitated using a radioenzymic assay, employing E coli DAG kinase and defined mixed micelle conditions to solubilize DAG and allow its quantitative conversion to [³³P] phosphatidic acid in the presence of [³³P]-γ-ATP. Following a number of extraction steps to remove unreacted [³³P]-γ-ATP, separation of [³³P] phosphatidic acid was achieved with the use of 1 ml Am-Prep™ minicolumns.

Statistical analysis.

The Student's t-test was used to analyse the results. All data are expressed as the mean ± SEM. *P* values of <0.05 are accepted as statistically significant.

RESULTS

The chronic treatment of the obese mice and rats with the synthetic hGH 177-191 and analogues was evaluated by the measurements of a number of parameters including cumulative body weight gain and daily food consumption. During the treatment period, a clear reduction of cumulative body weight gain was observed in the hGH 177-191 treated male as well as female animals when compared with the appropriate control (**Figures 1A, 1B**). When the data were analysed and expressed as daily body weight gain, the treated male animals reduced their body weight gain from 0.22 ± 0.03 to 0.16 ± 0.04 g/day and the female animals from 0.30 ± 0.02 to 0.22 ± 0.04 g/day. The average daily body weight gains of the both male and female treated animals showed approximately 27% lower than those of the appropriate control groups. However, no significant difference in the average daily food consumption among the 4 groups was observed (**Figures 2A, 2B**). Similar positive results have also been observed with daily oral administration at $500\mu\text{g}/\text{kg}/\text{day}$. These anti-obesity actions of various analogues, as represented by Ref. No. 9403 (**Figure 11A**) were observed in obese mice. The synthetic analogues control body weight gain without affecting the

appetite of the treated animals (**Figure 11B**). The similar reduction of body weight gain was found also in Zucker fatty (fa/fa) rats during hGH 177-191 treatment via either daily intraperitoneal injection or intradermal implantation of a slow-release pellet (**Figures 3A, 3B**). The food consumption of the treated Zucker rats was 5 unchanged throughout the treatment period (**Figures 4A, 4B**). These data clearly demonstrated that the chronic treatment with hGH 177-191 peptide reduced the body weight gain without affecting food consumption.

As indicated by the measurements of epididymal and parametrical fat pads, 10 the treated mice significantly reduced their adipose tissue weights up to 20% in the males and 12% in the females as compared with the controls of the same sex (**Table 1**). Lipogenesis is subject to the supply of precursor metabolites such as glucose and acetate. The effect of hGH 177-191 or analogues was therefore determined by measuring the incorporation of [¹⁴C]-glucose into lipid in isolated 15 adipose tissues. The peptide hGH 177-191 and analogues (**Table 5**) reduced lipogenic activity *in vitro* more than 25% as compared with the control in isolated tissues from fatty Zucker rats. Decrease in lipogenesis of the adipose tissue isolated from hGH 177-191 treated mice was evident (**Figures 5A, 5B**). The tissue 20 lipogenic activity reduced from 2.80 ± 0.33 to 2.33 ± 0.21 pmol/mg tissue/min in male mice and from 3.36 ± 0.13 to 2.99 ± 0.21 pmol/mg tissue/min in female mice. The lipolytic activity in adipose tissues of the hGH 177-191 treated obese animals was found to increase significantly in both sexes (**Figures 6A, 6B**). These results are consistent with the reduction in adipose tissue mass and cumulative body 25 weight gain previously observed.

25

Table 2 depicts the effect of the hGH 177-191 treatment on the profiles of circulating levels of triglyceride and cholesterol. The total cholesterol in plasma was 30 significantly reduced from 4.44 ± 0.56 to 3.52 ± 0.39 mmol/l in the male animals but

the plasma levels of cholesterol in the treated female animals were only slightly lower than those of the control ones. On the other hand hGH 177-191 did not influence the plasma levels of triglyceride in both sexes. In the presence of hGH 177-191 and various analogues, the oxidation of fatty acids (**Figure 7**) and the release of glycerol (**Table 4**) in adipose tissues isolated from obese animals were enhanced. This is consistent with the increase in lipolytic activity of the hGH 177-191 treated adipose tissues. All these *in vivo* and *in vitro* actions on lipid metabolism by the synthetic hGH 177-191 and analogues appear to be the result of the stimulation of the release of the cellular messenger diacylglycerol (**Figure 8**) which in turn modulates the key lipolytic enzyme hormone-sensitive lipase (**Figure 9**) and lipogenic enzymes acetyl-CoA carboxylase (**Figures 10A, 10B**) in target organs.

Tables 6 and 7 show the *in vitro* antilipogenic and lipolytic activity of hGH 177-191 and two representative analogues (Ref Nos. 9604 and 9605) on human adipose tissue.

Table 8 shows similar positive lipolytic results on porcine adipose tissue. These results support the expectation that hGH 177-191 and peptide variants thereof shown to be effective in one mammal species will have efficacy in all mammals. Since corresponding sequences of non-human mammals are effectively peptide variants of the human sequence, it is also therefore expected that those corresponding sequences will be effective in other mammals including humans.

Figure 12 shows cumulative weight gain results for analogue Ref No. 9604 and 9605, showing exceptional efficacy of Ref No. 9604 in particular. This *in vivo* result is consistent with the enhanced *in vitro* activity of Ref No. 9604 and 9605 compared with hGH 177-191 (Ref No. 9401) shown in Tables 6, 7 and 8.

Figure 13 shows the result of long-term oral administration of analogue Ref No. 9604 at 500 µg/kg daily by oral gavage to ob/ob mice.

The *in vivo* and *in vitro* assay results reveal that non-cyclic peptide analogues
5 are generally inactive. (Ref Nos. 9402, 9411, 9611 and 9617 are non-cyclic). Inactivity also results from alanine substitution at position 178, 183 and 186, with activity being retained for all other alanine substitutions tested (except at 182 and 189 which lead to non-cyclicity) including one with two d-Alanine substitutions (Ref No. 9501). Ref No. 9606, with Arg replaced by Lys at position 178, also retains
10 activity, as does and Ref No. 9407 with Arg (183) replaced by Lys, and Ref No. 9408 which additionally has an amide bond between Lys (183) and Glu (186).

The inactivity of peptides having alanine substitutions at positions 183 and 186
15 is consistent with the importance of a stabilising salt bridge interaction between opposite charges on Arg (183) and Glu (186) in hGH 177-191. Maintenance of activity with Ref No. 9408 (with an amide bond between Lys (183) and Glu (186)) and with Ref No. 9407 (where Arg (183) is replaced by the similar positively charged Lys(183)) is consistent with the need for a stabilising bond, either covalent or salt-bridge, between position 183 and 186.

TABLE 1 Effect of synthetic hGH 177-191 peptide on body weight and adipose tissue mass of obese mice after 18-day chronic treatment. Animals were given a daily i.p. injection of either hGH 177-191 (200 µg/kg body weight) or equivalent volume of saline as control. All data represent the mean ± SEM of 6 animals (*p<0.1; **p<0.05).

Item	Male		Female	
	Control	Treated	Control	Treated
Initial body wt.(g)	47.5 ± 3.1	48.6 ± 2.0	46.7 ± 3.6	48.2 ± 3.4
Final body wt.(g)	51.4 ± 3.0	51.5 ± 2.3	52.1 ± 3.2	52.2 ± 2.9
Body wt.gain(g) ^(a)	3.9 ± 0.6	2.9 ± 0.6*	5.4 ± 0.4	4.0 ± 0.6**
Adipose tissue (g) ^(b)	3.18± 0.43	2.52± 0.25**	3.67± 0.54	3.26± 0.25**

- (a) The difference between the initial and final body weights were considered as body weight gain.
- (b) The intact epididymal or parametrical fat pads were the representative adipose tissues.

TABLE 2 Effect of synthetic hGH 177-191 on plasma levels of triglyceride and total cholesterol in obese mice after 18-day chronic treatment. Blood samples were collected from the cut tips of the tails of the anaesthetised animals. Data represent the mean ± SEM of 6 animals (*p<0.05).

Item	Male		Female	
	Control	Treated	Control	Treated
Triglyceride (mmol/l)	0.63 ± 0.26	0.58 ± 0.16	0.41 ± 0.19	0.38 ± 0.11
Cholesterol (mmol/l)	4.44 ± 0.56	3.52 ± 0.39*	3.01 ± 0.52	2.84 ± 0.29

- 41 -

TABLE 3 Female C57BL/6J (ob/ob) mice aged 26 weeks were randomly divided into two groups (Sample number = 6 in each group). The mice were given a daily intraperitoneal (i.p.) injection of analogue Ref No. 9403 (500 µg/kg body weight) or saline for 18 days. After 18 days, all animals were given saline for another 18 days.

Item	Treatment (Day 0-18)		Post-treatment (Day 20-36)	
	Drug	Ref No: 9403	Saline	Ref No: 9403
Initial body weight (g)	54.74 ± 4.96	51.50 ± 2.61	54.70 ± 4.15	54.08 ± 2.77
Final body weight (g)	54.42 ± 4.66	53.72 ± 2.46	56.70 ± 4.45	56.14 ± 2.42
Body weight gain (g)	-0.32 ± 0.23	2.22 ± 0.22	2.00 ± 0.24	2.06 ± 0.25
Ave. food consumption (g/mouse/day)	4.82 ± 0.22	4.88 ± 0.29	5.03 ± 0.13	5.03 ± 0.14
Blood glucose (mM)	6.2 ± 0.8	5.8 ± 0.9	6.0 ± 1.0	5.7 ± 0.07
Triglyceride (mM)	0.49 ± 0.10	0.60 ± 0.11	0.54 ± 0.15	0.57 ± 0.08

TABLE 4 *In vitro* effect of peptide analogues on the glycerol release during the lipolysis. Adipose tissues were isolated from male Zucker fatty (fa/fa) rats (12-14 week-old) and incubated with different concentrations of peptide or saline. Each test group contains 6 samples.

Peptide concentration (µM)	Glycerol release (µmol/g tissue/hr)			
	Analogues			
	Ref No. 9401	Ref No. 9403	Ref No. 9407	Ref No. 9404
0	1.42 ± 0.04			
0.1	1.82 ± 0.02	1.80 ± 0.03	1.83 ± 0.11	1.75 ± 0.12
1.0	1.86 ± 0.12	1.88 ± 0.13	1.79 ± 0.07	1.94 ± 0.12

TABLE 5. *In vitro* effect of peptide analogues on the inhibition of lipogenesis. Isolated adipose tissues from male Zucker fatty (fa/fa) rats (12-14 week-old) were incubated with peptide (0.3 μ M) in KRB buffer containing exogenous insulin (0.1 mU/ml). The rate of [C^{14}]-glucose incorporation into [C^{14}]-lipid (nmol/g tissue/hr) was measured as the lipogenic activity of adipose tissues. Each test group contains 6 determinations.

Compound		<i>In vitro</i> lipogenesis		
Ref No. (description)	SEQ ID No.	nmol/g tissue/hr	% of control	Activity
Buffer control	-	243 \pm 13	100	=Inactive
9401(hGH 177-191)	1	181 \pm 10	75	Active
9402 (Cys(Acm) at 182 & 189)	5	222 \pm 9	91	Inactive
9403 (Lys at 179)	6	167 \pm 28	69	Active
9404 (CONH ₂)	7	187 \pm 18	77	Active
9405 (CH ₃ CO)	8	164 \pm 17	68	Active
9406 (Ala at 183)	9	236 \pm 17	97	Inactive
9407 (Lys at 183)	10	174 \pm 16	71	Active
9408 (Lys(183)-Glu(186) amide bond)	11	173 \pm 16	71	Active
9410 (desamino)	12	143 \pm 20	59	Active
9411 (Cys(SH) at 182 & 189)	13	225 \pm 15	93	Inactive
9501 (D-Ala at 187 & 190)	14	185 \pm 6	76	Active
9502 (Pen at 182,189)	15	174 \pm 5	72	Active
9601 (Ala at 191)	16	185 \pm 24	76	Active
9602 (Ala at 190)	17	176 \pm 27	73	Active
9603 (Ala at 178)	18	225 \pm 18	93	Inactive
9604 (Tyr elongation)	19	118 \pm 16	49	Active
9605 (Lys elongation)	20	184 \pm 41	76	Active
9606 (Lys at 178)	21	187 \pm 19	77	Active
9607 (Ala at 177)	22	198 \pm 12	82	Active
9608 (Ala at 179)	23	173 \pm 12	71	Active
9609 (Ala at 180)	24	188 \pm 13	78	Active
9610 (Ala at 181)	25	192 \pm 14	79	Active
9611 (Ala at 182)	26	224 \pm 19	93	Inactive
9612 (Ala at 184)	27	191 \pm 20	79	Active
9613 (Ala at 185)	28	189 \pm 16	78	Active
9614 (Ala at 186)	29	233 \pm 13	96	Inactive
9615 (Ala at 187)	30	183 \pm 17	76	Active
9616 (Ala at 188)	31	203 \pm 19	84	Active
9617 (Ala at 189)	32	223 \pm 16	92	Inactive
9618 (LysLys elongation)	33	188 \pm 19	77	Active

TABLE 6. Antilipogenic activity in Human Abdominal adipose Tissue.

¹⁴ C incorporation (Av DPM/mg tissue/hour)	
Control (BSA + Insulin 0.1 Mu/ml)	63 ± 5
hGH 177-191 0.1 μM	40 ± 3
Ref No 9605 0.1 μM	36 ± 2
Ref No 9604 0.1 μM	28 ± 3

TABLE 7. Lipolytic activity in Human Subcutaneous adipose Tissue

Glycerol released (nmol/mg tissue/hour)	
Control	480 ± 80
hGH 177-191 0.5 μM	1000 ± 80
Ref No 9605 0.5 μM	1100 ± 80
Ref No 9604 0.5 μM	1200 ± 80

TABLE 8 Lipolytic activity in Porcine adipose Tissue.

Glycerol released (nmol/mg tissue/hour)	
Control	300 ± 8
hGH 177-191 0.5 μM	1300 ± 160
Ref No 9605 0.5 μM	1350 ± 80
Ref No 9604 0.5 μM	1600 ± 20

REFERENCES:

1. Ultsch, M.H., Somers, W., Kossiakof, A.A. and DeVos, A.M. (1994), *J. Mol. Biol.* **236**: 286-299.
2. Ng, F.M., Bornstein, J., Welker, C., Zimmet, P.Z. and Taft, P. (1974). *Diabetes* **23**: 943-949.
3. Frigeri, L.G., Teguh, C., Lind.N., Wolff, G.L. and Lewis, U.J. (1988). *Endocrinology* **122**: 2940-2945.
4. Moore, W.V., Moore, K.C., McLachlan, C.G., Fuller, N.J., Burnett, G.B. and Frane, J.W. (1988). *Endocrinology* **122**: 2920-2926.
5. Zeisel, H.J., Petrykowski, W.V. and Wais, U. (1992). *Horm. Res.* **37** (Suppl.2): 5-13.
6. Wabitsch, M. and Heinze, E. (1993). *Horm. Res.* **49**: 5-9.
7. Christman, G.M. and Halme, J.K. (1992) *Fertil. Steril.* **57**: 12-14.
8. Jacobs, H.S. (1992) *Horm. Res.* **38** (Suppl.1): 14-21.
9. Crist, D.M., Peake, G.T., Loftfield, R.B., Kraner, J.C. and Egan, P.A. (1991) *Mech. Ageing Dev.* **58**: 191-205.
10. Strobl, J.S. and Thomas, M.J. (1994) *Pharm. Rev.* **46**: 1-34.
11. Raben, M.S. and Hollenberg, C.H. (1959) *J. Clin. Invest.* **38**: 484-488.

- 45 -

12. Bengtsson, B.A., Eden, S., Lonn, L., Kvist, H., Stokland, A., Lindstedt, G., Bosaeus, I., Tolli, J., Sjostrom, L. and Isaksson, O.G.P. (1993) *J. Clin. Endocrinol. Metab.* **76**: 309-317.
13. Skaggs, S.R. and Crist, D.M. (1991) *Horm. Res.* **35**: 19-24.
14. Etherton, T.D., Wiggins, J.P., Evock, C.M., Chung, C.S., Rebhun, J.F., Walton, P.E. and Steele, N.C. (1987). *J. Anim. Sci.* **64**: 433-443.
15. Jiang, W.J., Shih, I.L., Tsai, H., Huang, Y.T. and Koh, T.J. (1993). 13th American Peptide Symposium, Edmonton, Canada, P-334 (Abstract).
16. Gertner, J.M. (1993) *Horm. Res.* **40**: 10-15.
17. Davidson, M.B. (1987) *Endocrine Rev.* **8**: 115-131.
18. Tai, P.K., Liao, J.F., Chen, E.H., Dietz, J., Schwards, J. and Carter-Su, C. (1990) *J. Biol. Chem.* **265**: 21828-21834.
19. Dobo, M. (1975) PhD. Thesis, Department of Biochemistry, Monash University, Australia.
20. McNeillie, E.M. and Zammit, V.A. (1982) *Biochem. J.* **204**: 273-288.
21. Gertner, J.M. (1992) *Horm. Res.* **38** (Suppl.2): 41-43.
22. Ng, F.M., Adamafio, N.A. and Graystone, J.E. (1990) *J. Mol. Endocrinol.* **4**: 43-49.
23. Ng, F.M. and Heng, D. (1988) *Asia Pacific Commun. Biochem.* **2**: 47-51.

- 46 -

24. Fossati, P., Prencipe, L. (1982) *Clin. Chem.* **28**: 2077-80.
25. Allain, C.C., Poon, L.S., Chan, C.S.G., Richmond, W. and Fu, P.C. (1974) *Clin. Chem.* **20**: 470-475.
26. Harvey, S. *et al.*, "Growth Hormone", CRC Press (1995); Ascacio-Martinez *et al.* (1994), *Gene*, **143**:277-280; Castro-Peretta *et al.* (1995), *Gene*, **160**:311-312.

- 47 -

CLAIMS:

1. (Amended) A peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone, said carboxyl-terminal sequence containing amino acid residues 177-191 of human growth hormone:
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe,
or a corresponding sequence of a non-human mammalian growth hormone; wherein in said analogue
 - (i) amino acids at positions 182 and 189 of hGH are joined by a bond to promote a cyclic conformation; and/or
 - (ii) amino acids at positions 183 and 186 of hGH are joined by a salt bridge or a covalent bond;
or an organic or inorganic acid addition salt thereof.
2. (Cancelled).
3. (Cancelled).
4. (Cancelled).
5. (Cancelled).
6. (Cancelled).
7. (Amended) A peptide according to claim 1, wherein the bond between amino acids at positions 182 and 189 is a disulfide bond.

- 48 -

8. (Amended) A peptide according to claim 1, wherein the amino acids at positions 182 and 189 are selected from the group consisting of L-Cys, D-Cys, L-Pen and D-Pen.

9. (Amended) A peptide according to claim 16, wherein the amino acids at positions 183 and 186 are joined by a salt bridge, and are (X and Y) or (Y and X), respectively, where:
X is a positively charged amino acid, and
Y is a negatively charged amino acid.

10. A peptide according to claim 9, wherein X is selected from the group consisting of L- or D-Arg, Lys and Orn, and Y is selected from the group consisting of L- or D-Asp and Glu.

11. (Amended) A peptide according to claim 1, wherein the amino acids at positions 183 and 186 are joined by an amide covalent bond.

12. (Amended) A peptide according to claim 11, wherein the amino acids at positions 183 and 186 are (X and Y) or (Y and X), respectively, where:
X is selected from the group consisting of L- or D- Lys and Orn, and
Y is selected from the group consisting of L- or D- Asp and Glu.

13. (Amended) A peptide of the sequence:
 $X^1m\text{-Leu}\text{-Arg}\text{-Ile}\text{-Val}\text{-Gln}\text{-Cys}\text{-Arg}\text{ -Ser}\text{-Val}\text{-Glu}\text{-Gly}\text{-Ser}\text{-Cys}\text{-Gly}\text{-Phe}\text{-}X^2n$
wherein X^1 and X^2 are each selected from the group consisting of L- or D- Arg, His, Lys and Tyr, and m and n are each 0, 1, 2 or 3 with the proviso that at least m or n is 1;

- 49 -

a cyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

14. (Amended) A peptide of the sequence:
Y¹-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
wherein Y¹ is selected from the group consisting of the desamino form
(H), acetyl (CH₃CO-) and other acyl groups;
a cyclic disulfide thereof or an organic or inorganic acid addition salt
thereof.

15. (Amended) A peptide of the sequence:
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-Y²
wherein Y² is selected from the group of CONH₂ and alkyl amide
groups;
a cyclic disulfide thereof or an organic or inorganic acid addition salt
thereof.

16. (Amended) A peptide which is selected from the group
consisting of:

- 50 -

9605	<u>Lys</u> Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9618	<u>Lys Lys</u> Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9607	<u>Ala</u> Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9606	Leu <u>Lys</u> Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9608	Leu Arg <u>Ala</u> Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9403	Leu Arg <u>Lys</u> Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9609	Leu Arg Ile <u>Ala</u> Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9610	Leu Arg Ile Val <u>Ala</u> Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
9612	Leu Arg Ile Val Gln Cys Arg <u>Ala</u> Val Glu Gly Ser Cys Gly Phe
9613	Leu Arg Ile Val Gln Cys Arg Ser <u>Ala</u> Glu Gly Ser Cys Gly Phe
9615	Leu Arg Ile Val Gln Cys Arg Ser Val Glu <u>Ala</u> Ser Cys Gly Phe
9616	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly <u>Ala</u> Cys Gly Phe
9602	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys <u>Ala</u> Phe
9501	Leu Arg Ile Val Gln Cys Arg Ser Val Glu <u>D-Ala</u> Ser Cys <u>D-Ala</u> Phe
9601	Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly <u>Ala</u>

wherein the amino acid residue abbreviations used are in accordance
with the standard peptide nomenclature:

Gly	=	Glycine;	Ile	=	Isoleucine;
Glu	=	Glutamic Acid;	Phe	=	Phenylalanine;
Cys	=	Cysteine;	Arg	=	Arginine;
Gln	=	Glutamine;	Leu	=	Leucine;
Ser	=	Serine;	Val	=	Valine;
Lys	=	Lysine;	Ala	=	Alanine;
Asp	=	Aspartic acid;	His	=	Histidine;

- 51 -

Orn = Ornithine; Tyr = Tyrosine;

Pen = Penicillamine (β,β' -Dimethyl-Cysteine).

wherein all amino acids, except for glycine, are of the L-absolute configuration, unless indicated as D-absolute configuration, and the peptide has a cyclic disulfide bond between Cys(182) and Cys(189) or Pen(182) and Pen(189) as appropriate,
or an organic or inorganic acid addition salt thereof.

17. (Amended) A method for the treatment of obesity in an animal, which comprises administering to the animal an effective amount of a peptide according to any one of claims 1 or 7 to 16.

18. A method according to claim 17, wherein the animal is a human.

19. (Cancelled).

20. (Cancelled).

21. (Cancelled).

22. (Cancelled).

23. (Cancelled).

24. (Cancelled).

25. (Cancelled).

26. (Cancelled).

- 52 -

27. (Cancelled).

28. (Cancelled).

29. (Cancelled).

30. (Cancelled).

31. (Cancelled).

32. (Cancelled).

33. (Cancelled).

34. (Amended) A method according to claim 17 or claim 18, wherein the peptide is administered orally.

35. (Amended) Use of a peptide according to any one of claims 1 or 7 to 16 in the manufacture of a pharmaceutical composition for the treatment of obesity in an animal.

36. (Amended) A pharmaceutical composition for use in the treatment of obesity in an animal, which comprises an effective amount of a peptide according to any one of claims 1 to 7 or 16, together with one or more pharmaceutically acceptable carriers and/or diluents.

DRAFTING, EDITING
AND PROOFREADING

Frank Man-Woon NG
Woei-Jia JIANG

Attorney's Dkt. No. _____

Applicant or Patentee: _____

Serial or Patent No.: _____

Filed or Issued: _____

For: _____ TREATMENT OF OBESITY

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS [37 19(f) and 1.27(c)] - SMALL BUSINESS CONCERN**

I hereby declare that I am

the owner of the small business concern identified below:
 an official of the small business concern empowered to act on behalf of the concern identified below:
NAME OF CONCERN METABOLIC PHARMACEUTICALS LTD
ADDRESS OF CONCERN 10 Wallace Avenue, Toorak, Victoria, 3142, Australia

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled:

TREATMENT OF OBESITY

by inventors Frank Man-Woon NG and Woei-Jia JIANG described in

the specification filed herewith.
 application Serial No. _____, filed _____
 patent No. _____, issued _____

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d); or a nonprofit organization under 37 CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27)

Name _____
Address _____
 Individual Small Business Concern Nonprofit Organization

Name _____
Address _____
 Individual Small Business Concern Nonprofit Organization

I acknowledge the duty to file, in this application of patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28(b)]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING C. I. BELYEAE
TITLE OF PERSON OTHER THAN OWNER MANAGING DIRECTOR
ADDRESS OF PERSON SIGNING 10 Wallace Avenue, Toorak, Victoria, 3142, Australia
SIGNATURE Cheller DATE 18 March 2000

Frank Man-Woon NG
Applicant or Inventor: Woei-Jia JIANG Attorney's
Serial or Patent No.: _____ Docket No.: _____
Filed or Issued:
For: TREATMENT OF OBESITY

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) and 1.27(b)) - INDEPENDENT INVENTOR

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled TREATMENT OF OBESITY described in

the specification filed herewith
 application serial no. _____, filed _____
 patent no. _____, issued _____

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

no such person, concern, or organization
 persons, concerns or organizations listed below*

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

FULL NAME METABOLIC PHARMACEUTICALS LTD
ADDRESS 10 Wallace Avenue, Toorak, Victoria, 3142, Australia
 INDIVIDUAL SMALL BUSINESS CONCERN NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____
 INDIVIDUAL SMALL BUSINESS CONCERN NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____
 INDIVIDUAL SMALL BUSINESS CONCERN NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.


Frank Man-Woon NG


Woei-Jia JIANG

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR


Signature of Inventor


Signature of Inventor

Signature of Inventor


20/3/2000
Date

20/3/2000
Date

Date


1/21

Figure 1A




2/21


Figure 1B



3/21


Figure 2A

4/21

Figure 2B


5/21

Figure 3A




6/21

Figure 3B




7/21

Figure 4A




8/21

Figure 4B




9/21

Figure 5A




10/21

Figure 5B




11/21

Figure 6A




12/21

Figure 6B




13/21

Figure 7




14/21

Figure 8




15/21

Figure 9




16/21

Figure 10A




17/21

Figure 10B




18/21

Figure 11A




19/21

Figure 11B




20/21

Figure 12



21/21

Figure 13



- 1 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: NG, Frank M.
JIANG, Woei-Jia
- (ii) TITLE OF INVENTION: Treatment of Obesity
- (iii) NUMBER OF SEQUENCES: 33

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Metabolic Pharmaceuticals Ltd.
- (B) STREET: 10 Wallace Avenue
- (C) CITY: Toorak
- (D) STATE: Victoria
- (E) COUNTRY: Australia
- (F) ZIP: 3142

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: PO9001
- (B) FILING DATE: 8 September 1997
- (C) APPLICATION NUMBER: PP0398
- (D) FILING DATE: 13 November 1997

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Davies Collison Cave
- (B) REGISTRATION NUMBER:
- (C) REFERENCE/DOCKET NUMBER: 2093266

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: +613 9254 2777
- (B) TELEFAX: +613 9254 2770

- 2 -

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear or cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear or cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION:

X^{1m} Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe X²ⁿ
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear or cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION:

Y¹ Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

- 3 -

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear or cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION:

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe Y2
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Cys(Acm) at 182 and 189

Leu Arg Ile Val Gln Cys(Acm) Arg Ser Val Glu Gly Ser Cys(Acm) Gly
Phe 5 10 15

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Lys at 179

Leu Arg Lys Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

- 4 -

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: cyclic
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with CONH₂ replacing COOH

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe -CONH₂
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: cyclic
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with CH₃CO-HN replacing NH₂

(2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: cyclic
- (ii) MOLECULE TYPE: peptide

(iii) SEQUENCE DESCRIPTION: bGU 157 161 with all at 162

Leu Arg Ile Val Gln Cys Ala Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

- 5 -

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Lys at 183

Leu Arg Ile Val Gln Cys Lys Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: bicyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Lys at 183 and amide bond between 183 and 186

| |
Leu Arg Ile Val Gln Cys Lys Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION:hGH 177-191 with H replacing NH₂

H Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

- 6 -

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Cys(SH) at 182 and 189

Leu Arg Ile Val Gln Cys(SH) Arg Ser Val Glu Gly Ser Cys(SH) Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with D-Ala at 187 and 190

Leu Arg Ile Val Gln Cys Arg Ser Val Glu D-Ala Ser Cys D-Ala Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Pen at 182 and 189

Leu Arg Ile Val Gln Pen Arg Ser Val Glu Gly Ser Pen Gly Phe
1 5 10 15

- 7 -

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 191

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Ala
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 190

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Ala Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 178

Leu Ala Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

- 8 -

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: Tyr - hGH 177-191

Tyr Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: Lys - hGH 177-191

Lys Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

- 9 -

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Lys at 178

Leu Lys Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 177

Ala Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 179

Leu Arg Ala Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

- 10 -

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 180

Leu Arg Ile Ala Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 181

Leu Arg Ile Val Ala Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 182

Leu Arg Ile Val Gln Ala Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

- 11 -

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 184

Leu Arg Ile Val Gln Cys Arg Ala Val Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 185

Leu Arg Ile Val Gln Cys Arg Ser Ala Glu Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 186

Leu Arg Ile Val Gln Cys Arg Ser Val Ala Gly Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

- 12 -

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 187

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Ala Ser Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 188

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ala Cys Gly Phe
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: hGH 177-191 with Ala at 189

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Ala Gly Phe
1 5 10 15

- 13 -

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: cyclic

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: Lys-Lys- hGH 177-191

Lys Lys Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
1 5 10 15

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TREATMENT OF OBESITY™

the specification of which (check one)

is attached hereto

was filed on 4 September 1998 Application Serial No. PCT/AU98/00724 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in Title 37, Code of Federal Regulations § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

NUMBER	COUNTRY	DAY/MONTH/YEAR FILED	PRIORITY CLAIMED
PO 9001	Australia	8 September 1997	Yes
PP 0398	Australia	13 November 1997	Yes

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Stephen A. Bent, Reg. No. 29,768; David A. Blumenthal, Reg. No. 26,257; John J. Feldhaus, Reg. No. 28,822; Donald D. Jeffery, Reg. No. 19,980; Eugene M. Lee, Reg. No. 32,039; Peter G. Mack, Reg. No. 26,001; Brian J. McNamara, Reg. No. 32,789; Sybil Meloy, Reg. No. 22,749; George E. Quillin, Reg. No. 32,792; Colin G. Sandercock, Reg. No. 31,298; Bernhard D. Saxe, Reg. No. 28,665; Richard L. Schwaab, Reg. No. 25,479; Arthur Schwartz, Reg. No. 22,115; Harold C. Wegner, Reg. No. 25,258.

Send all correspondence to **FOLEY & LARDNER**, 3000 K Street, N.W., Suite 500, P.O. Box 25696, Washington, D.C. 20007-8696.
Address telephone communications to Stephen A. Bent at (202) 672-5300.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First or Sole Inventor <u>Frank Man-Woon NG</u>	Signature of First or Sole Inventor 	Date <u>20/3/2000</u>
Residence Address 144 Edgevale Road, Kew, <u>Victoria</u> , 3101, Australia	Country of Citizenship <u>Duf</u> Australia	
Post Office Address Same as above		

Signatures should conform to names as typewritten. Additional inventors on attached Page 2.

DECLARATION FOR PATENT APPLICATION AND APPOINTMENT OF ATTORNEY

Page _____

Full Name of Joint Inventor <u>Woei-Jia JIANG</u>	Citizenship Taiwanese
Residence Address <u>Unit 3, 19 Gardiner Road</u> <u>Flat 7, 86 Wellington Road, Clayton,</u> <u>Victoria, 3168, Australia</u>	Post Office Address <input checked="" type="checkbox"/> Same as Residence
DATE <u>X 20/3/2000</u>	SIGNATURE <u>x Woei-Jia JIANG</u>

Full Name of Joint Inventor	Citizenship
Residence Address	Post Office Address <input type="checkbox"/> Same as Residence
DATE	SIGNATURE

Full Name of Joint Inventor	Citizenship
Residence Address	Post Office Address <input type="checkbox"/> Same as Residence
DATE	SIGNATURE

Full Name of Joint Inventor	Citizenship
Residence Address	Post Office Address <input type="checkbox"/> Same as Residence
DATE	SIGNATURE

Full Name of Joint Inventor	Citizenship
Residence Address	Post Office Address <input type="checkbox"/> Same as Residence
DATE	SIGNATURE

Full Name of Joint Inventor	Citizenship
Residence Address	Post Office Address <input type="checkbox"/> Same as Residence
DATE	SIGNATURE